Clinical asset momentum TeraImmune has a recent clinical stage asset TI-168 and ongoing cGMP manufacturing development, signaling readiness for partner collaborations or license deals to accelerate clinical programs.

Regulatory T cell focus The company specializes in regulatory T cells and T cell– and B cell–targeting receptors, presenting a complementary fit for biopharma partners seeking immunomodulatory therapies or combination strategies.

Strategic partnerships Past and ongoing collaborations with NIAID and Baudax Bio indicate a track record of joint development and IND/shared research programs, suggesting appetite for new co-development or licensing opportunities.

Manufacturing capability With experience in establishing SOPs, QA/QC, regulatory services, and internal bench-to-clinic capability, TeraImmune can offer manufacturing support or outsourced process development for partners advancing cell therapies.

Funding and validation SBIR and PACT program awards, along with a measurable revenue range and a defined clinical pathway, provide credibility and a framework for engaging investors or strategic buyers seeking validated early-stage assets.